Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 2M | 3M | 5M |
| Gross Profit | 367K | 554K | 426K | 1M | 3M |
| Operating Income | -3M | -3M | -6M | -5M | -2M |
| EBITDA | -3M | -2M | -5M | -5M | -2M |
| Net Income | -3M | -3M | -6M | -6M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.23
+0.45% today
1Y Change
-99.07%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
China SXT Pharmaceuticals, Inc. (SXTC) is a Healthcare stock with listed on NASDAQ. The stock last traded around $2.23 and down 99.1% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -9.7%, EPS growth of -129.1%, a dividend yield of 0.0%. What stands out right now is revenue -9.7%, EPS -129.1%, free cash flow -21.3% with operating margin -224.1% and ROIC -9.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SXTC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SXTC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SXTC Max Drawdown
-99.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SXTC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.8M
+83.6% YoY
FY Net Income
-$2.7M
+52.1% YoY
Free Cash Flow
-$1.4M
-784.9% YoY
Revenue Growth
-9.7%
EPS Growth
-129.1%
Gross Margin
25.5%
Net Margin
-274.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2M | 2M | 2M | 3M | 5M |
| Gross Profit | 367K | 554K | 426K | 1M | 3M |
| Operating Income | -3M | -3M | -6M | -5M | -2M |
| EBITDA | -3M | -2M | -5M | -5M | -2M |
| Net Income | -3M | -3M | -6M | -6M | -3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 18M | 12M | 17M | 16M | 13M |
| Total Assets | 22M | 23M | 30M | 34M | 35M |
| Total Liabilities | 6M | 9M | 15M | 17M | 19M |
| Shareholder Equity | 15M | 14M | 15M | 16M | 16M |
| Total Debt | 984K | 3M | 4M | 2M | 43K |
| Net Debt | -17M | -9M | -14M | -13M | -13M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-590.7% YoY
Capital Expenditures
93K
-48.9% YoY
Free Cash Flow
1M
-784.9% YoY
Key ratios
Gross Margin
25.5%
Operating Margin
-224.1%
Net Margin
-274.4%
ROE
-14.7%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.